Effect of an Annular Closure Device (Barricaid) on Same-Level Recurrent Disk Herniation and Disk Height Loss After Primary Lumbar Discectomy

Parker, Scott L.; Grahovac, Gordan; Vukas, Duje; Vilendecic, Milorad; Ledić, Darko; McGirt, Matthew J.; Carragee, Eugene J.

doi:10.1097/bsd.0b013e3182956ec5

Cited by 90 publications

(108 citation statements)

References 30 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Wilke et al 45 studied this device in a human cadaveric disc model and the implant effectively prevented re-herniation without migration. Parker et al, 46 in a prospective 2-year trial, demonstrated a 0% re-herniation rate (vs. 6.5% for the control cohort), no complications, and a trend toward less disc height loss with the utilization of the Barricaid™. Another closure device, Xclose Tissue Repair System™ (Anulex Technologies, Minnetonka, MN), uses suture/ anchor combination to directly repair the annular defect.…”

Section: Annular Repairmentioning

confidence: 94%

Recurrent disc herniation: Etiology, evaluation, treatment, outcomes, and prevention (annular repair)

Khalsa

Amorosa

2016

Seminars in Spine Surgery

View full text Add to dashboard Cite

Section: Annular Repairmentioning

confidence: 94%

Recurrent disc herniation: Etiology, evaluation, treatment, outcomes, and prevention (annular repair)

Khalsa

Amorosa

2016

Seminars in Spine Surgery

View full text Add to dashboard Cite

“…Besides contributing to reherniation risk, defects in the annulus result in altered biomechanical response (30–32), decreased cellularity (33), accelerated degeneration (34) and decreased IVD height (25). The Barricaid (Intrinsic Therapeutics, Inc., Woburn, Massachusetts), a shield within the annulus fibrosus secured to the inferior vertebral body (35) prevents reherniation (36) and protects the facet joint (37), but does not seal AF defects. Developing biomaterials that can seal AF defects is an area of active research (38).…”

Section: Introductionmentioning

confidence: 99%

Effects of Level, Loading Rate, Injury and Repair on Biomechanical Response of Ovine Cervical Intervertebral Discs

et al. 2018

View full text Add to dashboard Cite

A need exists for pre-clinical large animal models of the spine to translate biomaterials capable of repairing intervertebral disc (IVD) defects. This study characterized the effects of cervical spinal level, loading rate, injury and repair with genipin-crosslinked fibrin (FibGen) on axial and torsional mechanics in an ovine cervical spine model. Cervical IVDs C2-C7 from nine animals were tested with cyclic tension-compression (- 240 to 100 N) and cyclic torsion (± 2° and ± 4°) tests at three rates (0.1, 1 and 2 Hz) in intact, injured and repaired conditions. Intact IVDs from upper cervical levels (C2-C4) had significantly higher torque range and torsional stiffness and significantly lower axial range of motion (ROM) and tensile compliance than IVDs from lower cervical levels (C5-C7). A tenfold increase in loading rate significantly increased torque range and torsional stiffness 4-8% (depending on amplitude) (p < 0.001). When normalized to intact, FibGen significantly restored torque range (FibGen: 0.96 ± 0.14, Injury: 0.88 ± 0.14, p = 0.03) and axial ROM (FibGen: 1.00 ± 0.05, Injury: 1.04 ± 0.15, p = 0.02) compared to Injury, with a values of 1 indicating full repair. Cervical spinal level must be considered for controlling biomechanical evaluations, and FibGen restored some torsional and axial biomechanical properties to intact levels.

show abstract

“…Some annular closure devices and NP replacement devices have been introduced clinically, including Barricaid (Intrinsic Therapeutics, Woburn, MA, USA), Xclose Tissue Repair System (Anulex Technologies, Minnetonka, MN), Inclose Surgical Mesh System (Anulex Technologies, Inc., Minnetonka, MN), NuCore® Injectable Nucleus hydrogel (Spine Wave, Inc., Shelton, CT, USA), NeuDIsc (Replication Medical, Inc., Cranberry, NJ), DiscCell (Gentis, Wayne, Pennsylvania), DASCOR Disc Arthroplasty System (Disc Dynamics, Inc., Eden Prairie, Minnesota), BioDisc (CryoLife, Atlanta, Georgia), and NucleoFix (Replication Medical, Inc., Cranberry, NJ) . The Barricaid AF closure device showed midterm clinical feasibility, efficacy, and safety . Although an FDA panel confirmed its efficacy in preventing reherniations following discectomy, the presence of lytic endplate lesions and device subsidence raised safety concerns .…”

Section: Available Clinical Treatments For Discogenic Painmentioning

confidence: 99%

Discogenic Back Pain: Literature Review of Definition, Diagnosis, and Treatment

et al. 2019

View full text Add to dashboard Cite

Discogenic back pain is multifactorial; hence, physicians often struggle to identify the underlying source of the pain. As a result, discogenic back pain is often hard to treat—even more so when clinical treatment strategies are of questionable efficacy. Based on a broad literature review, our aim was to define discogenic back pain into a series of more specific and interacting pathologies, and to highlight the need to develop novel approaches and treatment strategies for this challenging and unmet clinical need. Discogenic pain involves degenerative changes of the intervertebral disc, including structural defects that result in biomechanical instability and inflammation. These degenerative changes in intervertebral discs closely intersect with the peripheral and central nervous systems to cause nerve sensitization and ingrowth; eventually central sensitization results in a chronic pain condition. Existing imaging modalities are nonspecific to pain symptoms, whereas discography methods that are more specific have known comorbidities based on intervertebral disc puncture and injection. As a result, alternative noninvasive and specific diagnostic methods are needed to better diagnose and identify specific conditions and sources of pain that can be more directly treated. Currently, there are many treatments/interventions for discogenic back pain. Nevertheless, many surgical approaches for discogenic pain have limited efficacy, thus accentuating the need for the development of novel treatments. Regenerative therapies, such as biologics, cell‐based therapy, intervertebral disc repair, and gene‐based therapy, offer the most promise and have many advantages over current therapies. © 2019 The Authors. JBMR Plus Published by Wiley Periodicals, Inc. on behalf of American Society for Bone and Mineral Research

show abstract

Effect of an Annular Closure Device (Barricaid) on Same-Level Recurrent Disk Herniation and Disk Height Loss After Primary Lumbar Discectomy

Cited by 90 publications

References 30 publications

Recurrent disc herniation: Etiology, evaluation, treatment, outcomes, and prevention (annular repair)

Recurrent disc herniation: Etiology, evaluation, treatment, outcomes, and prevention (annular repair)

Effects of Level, Loading Rate, Injury and Repair on Biomechanical Response of Ovine Cervical Intervertebral Discs

Discogenic Back Pain: Literature Review of Definition, Diagnosis, and Treatment

Contact Info

Product

Resources

About